Targeted molecular therapy for myasthenia gravis

Shigeaki Suzuki

doi:10.1016/S1474-4422(21)00173-3

Targeted molecular therapy for myasthenia gravis

Shigeaki Suzuki

Department of Internal Medicine (Neurology)

Research output: Contribution to journal › Comment/debate › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	499-500
Number of pages	2
Journal	The Lancet Neurology
Volume	20
Issue number	7
DOIs	https://doi.org/10.1016/S1474-4422(21)00173-3
Publication status	Published - 2021 Jul

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/S1474-4422(21)00173-3

Cite this

@article{db849b3ae5184961b904cfd4677ad395,

title = "Targeted molecular therapy for myasthenia gravis",

author = "Shigeaki Suzuki",

year = "2021",

month = jul,

doi = "10.1016/S1474-4422(21)00173-3",

language = "English",

volume = "20",

pages = "499--500",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "7",

}

TY - JOUR

T1 - Targeted molecular therapy for myasthenia gravis

AU - Suzuki, Shigeaki

PY - 2021/7

Y1 - 2021/7

UR - http://www.scopus.com/inward/record.url?scp=85107949787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107949787&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(21)00173-3

DO - 10.1016/S1474-4422(21)00173-3

M3 - Comment/debate

C2 - 34146498

AN - SCOPUS:85107949787

SN - 1474-4422

VL - 20

SP - 499

EP - 500

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 7

ER -

Targeted molecular therapy for myasthenia gravis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this